NCT04702490View on ClinicalTrials.gov

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

PHASE2UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

April 30, 2022

Study Completion Date

June 30, 2022

Conditions
NASHNASH - Nonalcoholic SteatohepatitisType 2 DiabetesDiabetes Type 2DiabetesFatty LiverFatty Liver, NonalcoholicNAFLD
Interventions
DRUG

MET409 Active

MET409 Active (50mg)

DRUG

MET409 Placebo

MET409 Placebo (50mg)

DRUG

Empagliflozin

Empagliflozin (10mg)

Trial Locations (2)

33907

Metacrine Investigative Site, Fort Myers

78215

Metacrine Investigative Site, San Antonio

Sponsors

Lead Sponsor

Metacrine, Inc.
All Listed Sponsors
lead

Metacrine, Inc.

INDUSTRY

NCT04702490 - Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH | Biotech Hunter | Biotech Hunter